During the last session, Ventyx Biosciences Inc (NASDAQ:VTYX)’s traded shares were 0.88 million, with the beta value of the company hitting 0.51. At the end of the trading day, the stock’s price was $1.71, reflecting an intraday gain of 1.79% or $0.03. The 52-week high for the VTYX share is $11.48, that puts it down -571.35 from that peak though still a striking 8.19% gain since the share price plummeted to a 52-week low of $1.57. The company’s market capitalization is $120.91M, and the average intraday trading volume over the past 10 days was 1.37 million shares, and the average trade volume was 1.88 million shares over the past three months.
Ventyx Biosciences Inc (VTYX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.67. VTYX has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.55.
Ventyx Biosciences Inc (NASDAQ:VTYX) trade information
Ventyx Biosciences Inc (VTYX) registered a 1.79% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.79% in intraday trading to $1.71, hitting a weekly high. The stock’s 5-day price performance is -1.16%, and it has moved by -12.76% in 30 days. Based on these gigs, the overall price performance for the year is -25.33%. The short interest in Ventyx Biosciences Inc (NASDAQ:VTYX) is 6.37 million shares and it means that shorts have 3.4 day(s) to cover.
The consensus price target of analysts on Wall Street is $45, which implies an increase of 96.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $60 respectively. As a result, VTYX is trading at a discount of -3408.77% off the target high and -250.88% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -148.81%. While earnings are projected to return 36.48% in 2025, the next five years will return 18.81% per annum.
VTYX Dividends
Ventyx Biosciences Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Ventyx Biosciences Inc (NASDAQ:VTYX)’s Major holders
Ventyx Biosciences Inc insiders own 4.49% of total outstanding shares while institutional holders control 87.94%, with the float percentage being 92.08%. DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) is the largest shareholder of the company, while 165.0 institutions own stock in it. As of 2024-06-30, the company held over 5.83 million shares (or 9.4284% of all shares), a total value of $13.47 million in shares.
The next largest institutional holding, with 5.76 million shares, is of CITADEL ADVISORS LLC’s that is approximately 9.3133% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $13.3 million.
Also, the Mutual Funds coming in first place with the largest holdings of Ventyx Biosciences Inc (VTYX) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.78 shares. This amounts to just over 2.51 percent of the company’s overall shares, with a $3.04 million market value. The same data shows that the other fund manager holds slightly less at 1.71, or about 2.42% of the stock, which is worth about $2.93 million.
